INMED PHARMACEUTICALS INC. Finite-Lived Patents, Gross
INMED PHARMACEUTICALS INC. (INM) had Finite-Lived Patents, Gross of $1.19 million as of 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization › Intangible Asset, Finite-Lived, after Accumulated Amortization › Intangible Asset, Finite-Lived, before Accumulated Amortization
us-gaap:FiniteLivedPatentsGross · last filed 2024-11-14
- 2024-09-30: Finite-Lived Patents, Gross $1.19M.
- 2024-06-30: Finite-Lived Patents, Gross $1.19M.
- 2023-12-31: Finite-Lived Patents, Gross $1.19M.
- 2023-06-30: Finite-Lived Patents, Gross $300.00K; Finite-Lived Patents, Gross as first filed $1.19M.
| Period end | Finite-Lived Patents, Gross | Finite-Lived Patents, Gross as first filed |
|---|---|---|
| 2024-09-30 | $1.19M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $1.19M 10-Q · filed 2024-11-14 | |
| 2023-12-31 | $1.19M 10-Q · filed 2024-02-13 | |
| 2023-06-30 | $300.00K 10-Q · filed 2024-11-14 | $1.19M 10-K · filed 2023-09-29 |
| 2023-03-31 | $1.19M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $1.19M 10-Q · filed 2023-02-17 | |
| 2022-09-30 | $1.19M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $1.19M 10-K · filed 2023-09-29 | |
| 2022-03-31 | $1.19M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $1.19M 10-Q · filed 2022-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |